Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18622307 | 0.82 | P2RX7 (0.47) | CTNNB1WNT3AP2RX7MAPTSMN1; SMN2 | |
| SCHEMBL27509594 | 0.78 | MEN1 (0.35) | CTNNB1WNT3AP2RX7MAPTSMN1; SMN2 | |
| SCHEMBL15148333 | 0.76 | APLNR (0.41) | CTNNB1WNT3AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL15096486 | 0.76 | LMNA (0.53) | CTNNB1WNT3AP2RX7MAPTSMN1; SMN2 | |
| SCHEMBL8523693 | 0.76 | CTNNB1 (0.52) | CTNNB1WNT3AMAPTALDH1A1HTT | |
| SCHEMBL8744790 | 0.75 | P2RX7 (0.54) | CTNNB1WNT3AP2RX7SMN1; SMN2L3MBTL1 | |
| SCHEMBL4550609 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7KMT2A | |
| SCHEMBL6317653 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7SMN1; SMN2NPC1 | |
| SCHEMBL22092246 | 0.75 | AGBL2 (0.38) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL5162955 | 0.74 | P2RX7 (0.44) | CTNNB1WNT3AP2RX7SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116323558-A | Compounds and methods for treating diseases | 艾特里提治疗有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2020123272-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-2951182-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-17 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2014120800-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120784-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | CTNNB1 4804/4885WNT3A 3169/4885P2RX7 630/4885 |
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CTNNB1 3517/4885WNT3A 4008/4885P2RX7 1888/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | CTNNB1 2623/4885WNT3A 3454/4885P2RX7 157/4885 |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | CTNNB1 1771/4885WNT3A 810/4885P2RX7 4411/4885 |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTNNB1 3517/4885WNT3A 4008/4885P2RX7 1888/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CTNNB1 2318/4885WNT3A 2218/4885P2RX7 221/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | CTNNB1 1771/4885WNT3A 810/4885P2RX7 4411/4885 |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE12 | CTNNB1 3806/4885WNT3A 4072/4885P2RX7 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.